Loading...

SomnoMed

ASX:SOM
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SOM
ASX
A$115M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Australia and internationally. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
SOM Share Price and Events
7 Day Returns
-1.4%
ASX:SOM
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-39%
ASX:SOM
-3.3%
AU Medical Equipment
4.9%
AU Market
SOM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SomnoMed (SOM) -1.4% -2.4% 0.8% -39% -32.9% 20.1%
AU Medical Equipment 4.1% 0.9% 0.8% -3.3% 38.7% 103.7%
AU Market -0% 1.5% 6.5% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • SOM underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • SOM underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
SOM
Industry
5yr Volatility vs Market

SOM Value

 Is SomnoMed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of SomnoMed to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for SomnoMed.

ASX:SOM Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:SOM
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.928 (1 + (1- 30%) (1.3%))
0.957
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.957 * 5.96%)
8.02%

Discounted Cash Flow Calculation for ASX:SOM using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for SomnoMed is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:SOM DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 8.02%)
2019 -5.80 Analyst x1 -5.37
2020 2.70 Analyst x1 2.31
2021 3.50 Analyst x1 2.78
2022 4.16 Est @ 18.77% 3.05
2023 4.73 Est @ 13.83% 3.22
2024 5.22 Est @ 10.38% 3.29
2025 5.64 Est @ 7.96% 3.29
2026 5.99 Est @ 6.26% 3.23
2027 6.30 Est @ 5.08% 3.14
2028 6.56 Est @ 4.25% 3.03
Present value of next 10 years cash flows A$21.98
ASX:SOM DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$6.56 × (1 + 2.31%) ÷ (8.02% – 2.31%)
A$117.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$117.68 ÷ (1 + 8.02%)10
A$54.42
ASX:SOM Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$21.98 + A$54.42
A$76.40
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$76.40 / 62.80
A$1.22
ASX:SOM Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$1.22
Current discount Discount to share price of A$1.83
= -1 x (A$1.83 - A$1.22) / A$1.22
-50%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of SomnoMed is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SomnoMed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SomnoMed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:SOM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.13
ASX:SOM Share Price ** ASX (2019-04-18) in AUD A$1.83
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 545 Publicly-Listed Companies 16.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SomnoMed.

ASX:SOM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:SOM Share Price ÷ EPS (both in AUD)

= 1.83 ÷ -0.13

-13.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SomnoMed is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • SomnoMed is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does SomnoMed's expected growth come at a high price?
Raw Data
ASX:SOM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
102.5%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.37x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SomnoMed, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SomnoMed's assets?
Raw Data
ASX:SOM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.34
ASX:SOM Share Price * ASX (2019-04-18) in AUD A$1.83
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:SOM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:SOM Share Price ÷ Book Value per Share (both in AUD)

= 1.83 ÷ 0.34

5.31x

* Primary Listing of SomnoMed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SomnoMed is overvalued based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess SomnoMed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. SomnoMed has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SOM Future Performance

 How is SomnoMed expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
102.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SomnoMed expected to grow at an attractive rate?
  • SomnoMed's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • SomnoMed's earnings growth is expected to exceed the Australia market average.
  • SomnoMed's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:SOM Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:SOM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 102.5%
ASX:SOM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 9.8%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.5%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:SOM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:SOM Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 98 1
2022-06-30 87 1
2021-06-30 76 8 4 3
2020-06-30 68 7 3 3
2019-06-30 62 -1 -10 3
ASX:SOM Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 67 -7 -8
2018-09-30 66 -8 -8
2018-06-30 64 -9 -9
2018-03-31 54 -9 -4
2017-12-31 50 -8 -4
2017-09-30 50 -5 -4
2017-06-30 49 -3 -3
2017-03-31 48 -1 -2
2016-12-31 47 0 -1
2016-09-30 45 1 0
2016-06-30 44 2 0
2016-03-31 42 2 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • SomnoMed's earnings are expected to grow significantly at over 20% yearly.
  • SomnoMed's revenue is expected to grow by 9.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:SOM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from SomnoMed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SOM Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30 0.07 0.07 0.07 3.00
2020-06-30 0.05 0.06 0.05 3.00
2019-06-30 -0.15 -0.15 -0.15 1.00
ASX:SOM Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.13
2018-09-30 -0.14
2018-06-30 -0.15
2018-03-31 -0.07
2017-12-31 -0.07
2017-09-30 -0.07
2017-06-30 -0.06
2017-03-31 -0.04
2016-12-31 -0.01
2016-09-30 0.00
2016-06-30 0.00
2016-03-31 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • SomnoMed is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess SomnoMed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SomnoMed has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SOM Past Performance

  How has SomnoMed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SomnoMed's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SomnoMed does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare SomnoMed's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SomnoMed's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
SomnoMed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SomnoMed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:SOM Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 67.47 -7.65 47.27
2018-09-30 65.54 -8.14 46.33
2018-06-30 63.61 -8.62 45.38
2018-03-31 53.75 -3.88 34.27
2017-12-31 50.50 -3.75 31.86
2017-09-30 49.91 -3.55 31.58
2017-06-30 49.33 -3.34 31.31
2017-03-31 47.93 -1.98 28.75
2016-12-31 46.54 -0.61 26.19
2016-09-30 45.31 -0.22 25.20
2016-06-30 44.08 0.17 24.21
2016-03-31 41.53 0.44 22.69
2015-12-31 38.97 0.72 21.17
2015-09-30 36.70 0.66 20.00
2015-06-30 34.44 0.60 18.82
2015-03-31 34.48 0.61 18.20
2014-12-31 34.52 0.63 17.58
2014-09-30 32.40 0.52 16.73
2014-06-30 30.27 0.41 15.89
2014-03-31 26.14 0.32 14.80
2013-12-31 22.02 0.24 13.70
2013-09-30 20.25 0.41 12.63
2013-06-30 18.49 0.59 11.56
2013-03-31 17.96 0.65 11.07
2012-12-31 17.43 0.72 10.57
2012-09-30 16.34 0.62 10.06
2012-06-30 15.25 0.52 9.54

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SomnoMed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if SomnoMed has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SomnoMed improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SomnoMed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SomnoMed has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SOM Health

 How is SomnoMed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SomnoMed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SomnoMed is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SomnoMed's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SomnoMed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 15.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SomnoMed Company Filings, last reported 3 months ago.

ASX:SOM Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 21.58 1.49 8.51
2018-09-30 21.58 1.49 8.51
2018-06-30 32.77 1.44 13.38
2018-03-31 32.77 1.44 13.38
2017-12-31 25.88 0.94 7.58
2017-09-30 25.88 0.94 7.58
2017-06-30 30.95 0.12 14.21
2017-03-31 30.95 0.12 14.21
2016-12-31 33.24 0.00 16.71
2016-09-30 33.24 0.00 16.71
2016-06-30 32.69 0.00 17.63
2016-03-31 32.69 0.00 17.63
2015-12-31 22.21 0.00 7.42
2015-09-30 22.21 0.00 7.42
2015-06-30 21.51 0.00 8.31
2015-03-31 21.51 0.00 8.31
2014-12-31 20.48 0.00 8.95
2014-09-30 20.48 0.00 8.95
2014-06-30 12.57 0.00 2.94
2014-03-31 12.57 0.00 2.94
2013-12-31 12.47 0.00 3.96
2013-09-30 12.47 0.00 3.96
2013-06-30 11.57 0.00 4.22
2013-03-31 11.57 0.00 4.22
2012-12-31 10.00 0.00 3.54
2012-09-30 10.00 0.00 3.54
2012-06-30 8.61 0.00 3.54
  • SomnoMed's level of debt (6.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 6.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • SomnoMed has less than a year of cash runway based on current free cash flow.
  • SomnoMed has less than a year of cash runway if free cash flow continues to grow at historical rates of 77.9% each year.
X
Financial health checks
We assess SomnoMed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SomnoMed has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SOM Dividends

 What is SomnoMed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SomnoMed dividends. Estimated to be 0.1% next year.
If you bought A$2,000 of SomnoMed shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SomnoMed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SomnoMed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:SOM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:SOM Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30 0.00 1.00
2022-06-30 0.00 1.00
2021-06-30 0.01 3.00
2020-06-30 0.00 3.00
2019-06-30 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SomnoMed has not reported any payouts.
  • Unable to verify if SomnoMed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SomnoMed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SomnoMed has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of SomnoMed's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess SomnoMed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SomnoMed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SomnoMed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SOM Management

 What is the CEO of SomnoMed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Neil Verdal-Austin
COMPENSATION A$471,884
TENURE AS CEO 0.4 years
CEO Bio

Mr. Neil Verdal-Austin has been the Chief Executive of SomnoMed Limited since November 19, 2018. Mr. Verdal-Austin served as Chief Financial Officer of SomnoMed Limited since October 15, 2008 until November 19, 2018 and serves as its Executive Vice President of Asia Pacific. Mr Verdal-Austin is a most experienced, very dynamic and business focused individual, having worked for medical device companies in South Africa, the UK and in Australia for over 25 years. He has a proven track record in various roles in SomnoMed, with many years of deep involvement in businesses in Europe, the US and Asia-Pacific.

CEO Compensation
  • Neil's compensation has been consistent with company performance over the past year.
  • Neil's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the SomnoMed management team in years:

4.5
Average Tenure
  • The tenure for the SomnoMed management team is about average.
Management Team

Neil Verdal-Austin

TITLE
Chief Executive Officer
COMPENSATION
A$472K
TENURE
0.4 yrs

Martin Weiland

TITLE
Executive Vice President of Sales and Marketing - Europe
COMPENSATION
A$535K

Kien Nguyen

TITLE
Executive President of North America
COMPENSATION
A$554K
TENURE
6.4 yrs

Jim Evanger

TITLE
Chief Executive Officer of Renew Sleep Solutions
COMPENSATION
A$459K
TENURE
2.7 yrs

Hervé Fiévet

TITLE
Chief Financial Officer

Jagdeep Bijwadia

TITLE
Chief Medical Officer

Terry Flitcroft

TITLE
Company Secretary
COMPENSATION
A$35K
AGE
59
TENURE
24.3 yrs

Peter Spencer

TITLE
General Manager of Operations
AGE
62

Chris Bedford

TITLE
Vice President of Global Production and Product Development
COMPENSATION
A$240K
Board of Directors Tenure

Average tenure of the SomnoMed board of directors in years:

7.2
Average Tenure
  • The tenure for the SomnoMed board of directors is about average.
Board of Directors

Peter Neustadt

TITLE
Non-Executive Chairman
COMPENSATION
A$310K
TENURE
6.8 yrs

Peter Cistulli

TITLE
Chairman of the Medical Advisory Board

Iven Klineberg

TITLE
Member of the Medical Advisory Board

Jack Gerschman

TITLE
Member of the Medical Advisory Board

Lee Ausburn

TITLE
Non-Executive Director
COMPENSATION
A$64K
TENURE
7.6 yrs

Rob Scherini

TITLE
Non-Executive Director
COMPENSATION
A$64K
TENURE
7.6 yrs

Hamish Corlett

TITLE
Non-Executive Director
COMPENSATION
A$11K
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
11. Mar 19 Sell Australian Ethical Investment Ltd Company 27. Nov 18 27. Nov 18 -23,000 A$2.01 A$-46,117
11. Mar 19 Buy Australian Ethical Investment Ltd Company 18. Jul 18 08. Mar 19 802,496 A$1.78 A$1,427,632
25. Jun 18 Buy Australian Ethical Investment Ltd Company 22. Jun 18 22. Jun 18 1,231,181 A$2.15 A$2,652,863
14. Jun 18 Buy TDM Growth Partners Company 11. Jun 18 14. Jun 18 1,014,453 A$2.26 A$2,292,664
08. Jun 18 Buy TDM Growth Partners Company 06. Jun 18 08. Jun 18 1,072,505 A$2.26 A$2,423,861
X
Management checks
We assess SomnoMed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SomnoMed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SOM News

Simply Wall St News

Did Changing Sentiment Drive SomnoMed's Share Price Down By 43%?

That downside risk was realized by SomnoMed Limited (ASX:SOM) shareholders over the last year, as the share price declined 43%. … Given that SomnoMed didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Meanwhile, the share price is down 43% over twelve months, which is disappointing given the progress made.

Simply Wall St -

How Many Insiders Bought SomnoMed Limited (ASX:SOM) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … SomnoMed Insider Transactions Over The Last Year. … Over the last year, we can see that insiders have bought 54.20k shares worth AU$163k.

Simply Wall St -

Can We See Significant Insider Ownership On The SomnoMed Limited (ASX:SOM) Share Register?

If you want to know who really controls SomnoMed Limited (ASX:SOM), then you'll have to look at the makeup of its share registry. … With a market capitalization of AU$98m, SomnoMed is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for SomnoMed

Simply Wall St -

What Does SomnoMed Limited's (ASX:SOM) Share Price Indicate?

received a lot of attention from a substantial price movement on the ASX over the last few months, increasing to A$3.25 at one point, and dropping to the lows of A$2.15. … A question to answer is whether SomnoMed's current trading price of A$2.16 reflective of the actual value of the? … Let’s take a look at SomnoMed’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

SomnoMed Limited’s (ASX:SOM) Insiders Ramped Up Holdings - Should You?

some insider buying over the past three months, with insiders investing in. … Generally, insiders buying more shares in their own firm sends a bullish signal … A research published in The MIT Press (1998) concluded that stocks following insider buying outperformed the market by 4.5%

Simply Wall St -

Is It The Right Time To Buy SomnoMed Limited (ASX:SOM)?

SomnoMed Limited (ASX:SOM), a medical equipment company based in Australia, saw significant share price volatility over the past couple of months on the ASX, rising to the highs of A$3.25 and falling to the lows of A$2.88. … Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. … SOM’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value.

Simply Wall St -

What Does SomnoMed Limited's (ASX:SOM) Ownership Structure Look Like?

In this article, I'm going to take a look at SomnoMed Limited’s (ASX:SOM) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … ASX:SOM Insider Trading Oct 24th 17 General Public Ownership The general public holds a substantial 29.16% stake in SOM, making it a highly popular stock among retail investors. … Private Company Ownership Another important group of owners for potential investors in SOM are private companies that hold a stake of 11.58% in SOM.

Simply Wall St -

SOM Company Info

Description

SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Australia and internationally. Its products include SomnoDent oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard, which protects patient’s from teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.

Details
Name: SomnoMed Limited
SOM
Exchange: ASX
Founded: 2004
A$114,617,606
62,804,168
Website: http://www.somnomed.com.au
Address: SomnoMed Limited
20 Clarke Street,
Level 3,
Crows Nest,
New South Wales, 2065,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX SOM Ordinary Shares Australian Securities Exchange AU AUD 27. Aug 2004
OTCPK SOMN.F Ordinary Shares Pink Sheets LLC US USD 27. Aug 2004
DB RJV Ordinary Shares Deutsche Boerse AG DE EUR 27. Aug 2004
Number of employees
Current staff
Staff numbers
0
SomnoMed employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 10:30
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/27
Last earnings filing: 2019/02/20
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.